P783: CLINICAL, HUMANISTIC, AND ECONOMIC BURDEN IN PATIENTS WITH PNH RECEIVING C5 INHIBITION TREATMENT ACROSS UK, GERMANY, AND FRANCE. INSIGHTS FROM THE COMMODORE BURDEN OF ILLNESS STUDY

• Louis Terriou,
• Maria Piggin,
• Pascale Burmester,
• Fengkui Zhang,
• Alan Finnegan,
• Persefoni Kritikou,
• Claudia Mighiu,
• Christian Buehrer,
• Pablo Katz,
• Selma Mode,
• Xenia Studera,
• Huong Trinh,
• Talha Munir

Affiliations

Louis Terriou

1 Service de Medicine Interne – Hematologie, CHRU de Lille, Lille, France

Maria Piggin

2 PNH Support, London, United Kingdom

Pascale Burmester

3 Stiftung Lichterzellen, Köln, Germany

Fengkui Zhang

4 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical University, Beijing, China

Alan Finnegan

5 University of Chester, chester, United Kingdom

Persefoni Kritikou

6 HCD Economics, Chester, United Kingdom

Claudia Mighiu

6 HCD Economics, Chester, United Kingdom

Christian Buehrer

7 F. Hoffmann-La Roche Ltd, Basel, Switzerland

Pablo Katz

7 F. Hoffmann-La Roche Ltd, Basel, Switzerland

Selma Mode

7 F. Hoffmann-La Roche Ltd, Basel, Switzerland

Xenia Studera

7 F. Hoffmann-La Roche Ltd, Basel, Switzerland

Huong Trinh

8 Genentech, Inc., South San Francisco, CA, United States

Talha Munir

9 Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom